Summit Therapeutics (SMMT) surged after fresh Phase III data showed its cancer drug ivonescimab extended survival in advanced lung cancer patients. Median survival was 16.8 months vs 14 on chemo, with Western patients reaching 17 months. The drug, already approved in China, has U.S. FDA Fast Track status. Summit stock is up 45.6% in 2025.